Development of Superagonist Analogs of Recombinant Human TSH for Imaging and Ther

用于成像和治疗的重组人 TSH 超级激动剂类似物的开发

• 批准号: 7536286
• 负责人: Bruce Dale Weintraub
• 金额: $ 89.46万
• 依托单位: TROPHOGEN, INC.
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-06-15 至 2010-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7536286
• 关键词: Ablation; Affinity; Beds; Bioreactors; Cancer Patient; Count; Data; Detection; Development; Diagnostic; Diagnostic Imaging; Disease regression; Dose; Early Diagnosis; End Point; Endocrine; Generations; Glycoproteins; Grant; High Pressure Liquid Chromatography; Hormones; Human; I125 isotope; Image; Immunoassay; In Vitro; Intramuscular; Intravenous; Iodine; Lead; Malignant Neoplasms; Malignant neoplasm of thyroid; Measurement; Medical Surveillance; Metabolic Clearance Rate; Methods; Modeling; Mus; Numbers; Organ; Papillary thyroid carcinoma; Patients; Phase; Plasma; Positron-Emission Tomography; Production; Protein Kinase Inhibitors; Public Health; Radio; Recombinants; Recurrent tumor; Reporting; Research Personnel; Rodent; Score; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Staging; Standards of Weights and Measures; Structure; Technology; Therapeutic; Therapeutic Effect; Thyroglobulin; Thyroid Gland; Thyroid carcinoma; Thyrotropin; Time; Tissues; Transfection; Transgenic Organisms; analog; cancer imaging; cancer therapy; clinically relevant; commercialization; expression vector; fluorodeoxyglucose; hormone analog; improved; in vitro Assay; in vivo; in vivo Bioassay; intraperitoneal; method development; mouse model; novel; protein kinase inhibitor; receptor binding; response; scale up; stable cell line; subcutaneous; thyroid neoplasm; tumor; uptake

DESCRIPTION (provided by applicant): Thyroid cancer is increasingly prevalent and the most common malignancy of endocrine tissues, and most patients require lifelong surveillance with diagnostic thyroid-stimulating hormone (TSH)-stimulated radioiodine uptake as well as thyroid remnant or tumor ablation with radioiodine therapy. The PI, who was both co-inventor and co-developer with Genzyme of wild type recombinant human (rh) TSH (Thyrogen) currently approved for stimulation of diagnostic radioiodine uptake and thyroglobulin secretion, now proposes to develop a more potent and more efficacious second generation superactive analog of rh TSH for the 15-20% of poorly responsive thyroid cancer patients in diagnostic imaging as well as for the majority of such patients for radioiodine therapy. Our previous structure-function studies resulted in the discovery of the first analogs of TSH and other glycoprotein hormones with major increases in receptor binding affinity and bioactivity. During our highly scored and successfully completed phase 1 SBIR study we have achieved all the aims including developing stable cell lines producing high levels of the final two candidate superactive analogs; optimization of large scale bioreactor production methods; development of a novel, high capacity purification methods suitable for commercial scale-up; rigorous quantification and characterization of purified analogs by multiple physicochemical methods, and proof of increased potency and efficacy in the now classic in vivo mouse rh TSH in vivo bioassay first developed by the PI. In the current phase 2 proposal, for which we have provided extensive preliminary data well beyond the aims of the phase 1 proposal, we plan to produce and purify additional large amounts (>200mg) of the final two TSH analog candidates TR1401 and 1402 in the fibrous bed bioreactor sufficient for all the phase two in vivo studies using the methods of production and purification optimized in the phase one study. We also plan to develop and validate a novel immunoassay for the detection of TSH analogs in unpurified rodent plasma that quantifies accurately and identically to rigorous HPLC methods which will then be used to determine the IV metabolic clearance rate and the IP, SC and IM phamacokinetics in rodents. Most importantly, in this phase two proposal we will examine for the first time multiple clinically relevant diagnostic and therapeutic endpoints of TSH action comparing TSH analogs TR1401 and 1402 to wild type (Genzyme) recombinant TSH in normal mice and in those with Ret/PTC1 and other transgenic mouse models of thyroid cancer. Specifically we will examine detailed dose response curves for both wild type and analog TSH in thyroidal 125I uptake by direct organ counting, diagnostic thyroidal PET imaging with 124I and 18 Fluorodeoxyglucose as well as therapeutic 131I -induced tumor regression. Finally, we will determine the possible complementation of the diagnostic and therapeutic effects of TR1401 and 1402 with those of selected newly developed protein kinase inhibitors in vitro and in vivo. PUBLIC HEALTH RELEVANCE: Thyroid cancer is the most common malignancy of endocrine tissues and most patients require lifelong surveillance with diagnostic thyroid-stimulating hormone (TSH)-stimulated radio-iodine imaging to detect recurrent tumor. The PI and Co- Investigator have developed a much improved form of TSH and propose a completely new method of thyroid cancer imaging that should greatly improve early detection and lead to improved cancer treatment and survival.

描述（由申请方提供）：甲状腺癌越来越普遍，是内分泌组织最常见的恶性肿瘤，大多数患者需要终身监测，诊断性促甲状腺激素（TSH）刺激的放射性碘摄取以及甲状腺残留或放射性碘治疗的肿瘤消融。该PI是Genzyme野生型重组人（rh）TSH的联合发明者和联合开发者（Thyrogen）目前已获批用于刺激诊断性放射性碘摄取和甲状腺球蛋白分泌，现在建议开发一种更有效的第二代rh TSH超活性类似物，用于15 - 20%在诊断成像中对反应不良的甲状腺癌患者以及大多数此类患者进行放射性碘治疗。我们先前的结构-功能研究发现了TSH和其他糖蛋白激素的第一个类似物，其受体结合亲和力和生物活性显著增加。在我们的高评分和成功完成的第1期SBIR研究中，我们实现了所有目标，包括开发稳定的细胞系，生产高水平的最后两种候选超活性类似物;优化大规模生物反应器生产方法;开发适用于商业规模的新型高容量纯化方法;通过多种物理化学方法对纯化的类似物进行严格的定量和表征，并证明PI首次开发的现在经典的小鼠体内rh TSH体内生物测定法的效力和功效增加。在目前的第二阶段提案中，我们提供了远远超出第一阶段提案目标的大量初步数据，我们计划生产和纯化额外的大量（> 200毫克）纤维床生物反应器中的最终两种TSH类似物候选物TR1401和1402足以用于使用在第一阶段中优化的生产和纯化方法的所有第二阶段体内研究study.我们还计划开发并验证一种用于检测未纯化啮齿动物血浆中TSH类似物的新型免疫测定法，该免疫测定法可准确定量，且与严格的HPLC方法相同，然后将其用于测定啮齿动物的IV代谢清除率以及IP、SC和IM药物代谢。最重要的是，在这个第二阶段的提案中，我们将首次检查TSH作用的多个临床相关诊断和治疗终点，比较TSH类似物TR1401和1402与野生型（Genzyme）重组TSH在正常小鼠和Ret/PTC 1和其他甲状腺癌转基因小鼠模型中的作用。具体而言，我们将通过直接器官计数、124 I和18氟脱氧葡萄糖诊断性甲状腺PET成像以及治疗性131 I诱导的肿瘤消退来检查甲状腺125 I摄取中野生型和类似物TSH的详细剂量反应曲线。最后，我们将确定TR1401和1402的诊断和治疗效果与选定的新开发的蛋白激酶抑制剂在体外和体内的可能互补。公共卫生相关性：甲状腺癌是内分泌组织最常见的恶性肿瘤，大多数患者需要终身监测，诊断促甲状腺激素（TSH）刺激的放射性碘成像，以检测复发性肿瘤。PI和合作研究者开发了一种改进的TSH形式，并提出了一种全新的甲状腺癌成像方法，该方法应大大提高早期检测，并改善癌症治疗和生存率。